HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2455 Teprotumumab (Anti-IGF-1R / CD221) Teprotumumab (Anti-IGF-1R / CD221) is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab can be used for thyroid-associated ophthalmopathy research.MW: 145.5 KD. Human IgG1
A2456 Ganitumab (Anti-IGF-1R / CD221) Ganitumab (Anti-IGF-1R / CD221) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. MW: 145.5 KD. Human IgG1
A2457 Xentuzumab (Anti-IGF-1) Xentuzumab (Anti-IGF-1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF-1 and IGF-2. Xentuzumab inhibits both of IGF-1 and IGF-2 growth-promoting signalling and suppresses AKT activation. MW: 145.5 KD. Human IgG1
A2460 Anifrolumab (Anti-IFNAR1) Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD. Human IgG1
A2461 Sifalimumab (Anti-IFNa1) Sifalimumab (Anti-IFNa1) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. MW: 145.5 KD. Human IgG1
A2462 Feladilimab (Anti-ICOS / CD278) Feladilimab (Anti-ICOS/CD278) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has potential for its use in cancer research. MW: 145.5 KD. Human IgG4PE
A2463 Vopratelimab (Anti-ICOS / CD278) Vopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD. Human IgG1
A2464 Bersanlimab (Anti-ICAM1 / CD54) Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD. Human IgG1
A2465 Anti-HLA-DR Anti-HLA-DR (IMMU-114) is a humanized anti-human leukocyte antigen-DR (HLA-DR) moAb, that depletes APCs and reduces alloreactive T cells. MW: 145.5 KD. Human IgG4SP
A2466 Derlotuximab (Anti-Histone H1) Derlotuximab is a recombinant human monoclonal antibody that targets DNA/histone (H1) complex. It is potentially used in the treatment of Glioblastoma multiforme (GBM), Cancers, brain, malignant glioma, Solid tumors. It is also used in certain immunoassay techniques. MW: 145.5 KD. Human IgG1
A2470 Anti-Hepcidin / HAMP Anti-Hepcidin / HAMP (LY2787106) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export. MW: 145.5 KD. Human IgG4SP
A2471 Anti-HBEGF Anti-HBEGF (U3-1565) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which prevents EGF receptor activation and results in subsequent induction of cell growth signaling. MW: 145.5 KD. Human IgG1
A2472 Indusatumab (Anti-GUCY2C) Indusatumab (Anti-GUCY2C) is an monoclonal antibody that targets GUCY2C (Guanylate cyclase 2C). MW: 145.5 KD. Human IgG1
A2473 Anti-GPRC5D Anti-GPRC5D is a specific antibody against G protein-coupled receptor C5 family member D (GPRC5D). Human IgG1
A2474 Petosemtamab (Anti-EGFR / LGR5) Petosemtamab (Anti-EGFR/LGR5) is a highly potent bispecific antibody against EGFR (Kd 0.22 nM) and LGR5 (Kd 0.86 nM). It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD. Human IgG1
A2475 Glembatumumab (Anti-GPNMB) Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. MW: 145.5 KD. Human IgG2SA
A2476 Codrituzumab (Anti-GPC3 / Glypican-3) Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD. Human IgG1
A2478 Glenzocimab (Anti-GP6 / Glycoprotein-6) Glenzocimab (Anti-GP6 / Glycoprotein-6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. MW: 145.5 KD. Human IgG1
A2480 Anti-GFRAL Anti-GFRAL (NGM120) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL activity which prevents binding of growth differentiation factor 15 (GDF15; MIC-1) to its receptor GFRAL and prevents GDF15/GFRAL-mediated signaling. MW: 145.5 KD. Human IgG1
A2481 Nadecnemab (Anti-GFRA3) Nadecnemab (Anti-GFRA3) is an IgG4κ antibody targeting GFRA3 (glial cell derived neurotrophic factor family receptor alpha 3). Nadecnemab can be used for research of osteoarthritis of the knee/pain. MW: 145.5 KD. Human IgG4SP